Article

Hyaluronic acid gel injections treat facial rhytidosis

The use of hyaluronic acid gel injections from non-animal sources is a safe, long-lasting treatment for facial rhytidosis, based on the results of a 5-year study of clinical experience with the filling agent.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Related Content
(Image credit: AdobeStock/Nadiia) Mount Sinai’s NYEE unveils Center for Refractive Solutions
June 17th 2025

Mount Sinai’s NYEE unveils Center for Refractive Solutions

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Q&A: Sunir Garg, MD, shares insights on using chlorhexidine for anti-sepsis
May 29th 2025

Q&A: Sunir Garg, MD, shares insights on using chlorhexidine for anti-sepsis

Ehsan Sadri, MD, leads an ophthalmology innovation discussion with Jeffry Weinhuff of Visionary Ventures
March 29th 2024

(EyePod) From idea to impact: Navigating ophthalmic innovation

Q&A: Tarek Hassan, MD, on a new retinotomy technique
May 23rd 2025

Q&A: Tarek Hassan, MD, on a new retinotomy technique

Q&A: Kapil Mishra on radiation retinopathy in uveal melanoma
May 21st 2025

Q&A: Kapil Mishra on radiation retinopathy in uveal melanoma

© 2025 MJH Life Sciences

All rights reserved.